TrialThe lancet. Diabetes & endocrinology2017

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.

Paresh Dandona et al.PubMed ↗Publisher ↗

No numbers read from the abstract.